Business Wire

UAE-FED-NATIONAL-COUNCIL

9.1.2019 19:16:14 CET | Business Wire | Press release

Share
European Parliament President Calls for Strengthening Cooperation with UAE in Humanitarian, Relief Work

His Excellency Antonio Tajani, President of the European Parliament, expressed his deep appreciation for the UAE’s global humanitarian and relief efforts, manifested through the work of the Emirates Red Crescent and described them as “really impressive”.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190109005738/en/

His statement came during a brief speech delivered on Tuesday, January 8, 2019, during the opening of the three-day ‘Humanitarian Aid for Stability’ exhibition at the European Parliament in Brussels, Belgium. The event was organized by the Emirates Red Crescent in coordination with the Federal National Council (FNC), the parliamentary body of the UAE.

The opening of the exhibition drew the participation of Her Excellency Dr Amal Al Qubaisi, Speaker of FNC, His Excellency Fahad Abdelrahman Bin Sultan, Deputy Secretary General for International Aid at the Emirates Red Crescent, members of the European Parliament, and several ambassadors.

His Excellency Antonio Tajani called for joint action between the UAE and Europe to deal with illegal immigration, expand cooperation in this regard to the Middle East and Africa, and strengthen collaborative efforts to combat terrorism and enhance security. He added that ensuring stability and promoting development efforts in the world are common goals for the UAE and the EU.

His Excellency Antonio Tajani stressed that the refugee crisis is a global challenge, and therefore humanitarian aid must be a collective task that engages nations and peoples.

Furthermore, he thanked Antonio López-Istúriz White, Secretary General of the European People’s Party and member of the European Parliament, for his initiative in holding the exhibition that presented a novel opportunity to showcase the endeavors of valued partners of the EU to help alleviate the devastating effects of war. He added that war and natural disasters are the reasons for thousands of migrants trying to seek refuge in Europe.

His Excellency Antonio Tajani said: “The exhibition carries the positive message of hope. Yes, hope, because helping each other, providing a roof for people in need is providing hope, and hope is the fuel for a better tomorrow.”

In closing, he invited guests to view the exhibition that included a model of the Mrajeeb Al Fhood camp for Syrian refugees in Jordan and an interactive world map of areas in which the Emirates Red Crescent operates. He also highlighted the EU’s humanitarian commitment to helping refugees that places it at the forefront of humanitarian aid providers globally, and called for reinstating stability and security in the refugees’ home countries to overcome this global challenge.

Speaking on the sidelines of the launch of the exhibition, His Excellency Fahad Abdelrahman Bin Sultan said: “The humanitarian and development aid offered by the UAE to the world amounted to US$32.01 billion from 2013 to 2017 and benefited millions of people across the globe, including 10 million Yemenis.”

He added: “This exhibition is the first of its kind outside the UAE and was organized at the request of the European Parliament to explore the UAE’s international humanitarian, relief, and development role that is based on the country’s noble values and enhances the global humanitarian ecosystem.”

His Excellency Fahad Abdelrahman Bin Sultan stressed that the UAE humanitarian and development aid focuses on meeting the needs of refugees and displaced civilians in volatile areas, such as Syria, Yemen, Somalia, Palestine, Afghanistan, and Iraq. He pointed out that the UAE has gained international respect and trust, and placed first globally for the fifth consecutive year for its contribution of humanitarian and development aid relative to national GDP.

He noted that more than 100 countries have benefited from aid provided by the UAE, adding that the Emirates Red Crescent has 14 offices in countries such as Yemen, Somalia, Kazakhstan, Indonesia, Pakistan, Afghanistan, Bosnia, and Albania.

His Excellency Fahad Abdelrahman Bin Sultan outlined the distribution of the UAE humanitarian aid as follows: US$4.92 billion to Yemen from April 2015 to December 2018, around US$174.6 million to Libya from 2013 to 2017, around US$963.5 million to the Syrian people from 2012 to November 2018, around US$641.5 million to the people of Erbil (Iraq) from 2013 to 2017, around US$233.3 million to Somalia from 2013 to 2017, US$489 million to Palestinians from 2013 to 2018, and US$333.3 million to Afghanistan from 2013 to 2017.

*Source: AETOSWire

Contact:

Federal National Council, United Arab Emirates : Mohammed Al-Sawafi, +971506183874 m.alsawwafi@almajles.gov.ae Twitter: @FNC_UAE

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye